DAIICHI SANKYO CO LTD (DSKYY/DSKYY.PK) Wrap Up:

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company?s products primarily include Olmesartan, an antihypertensive agent, which is marketed as Olmetec in Japan and Europe, as Benicar in the Unites States, and as Olvance in India; Levofloxacin, a synthetic antibacterial agent that is marketed as Cravit in Japan and other Asian countries; and Pravastatin, an antihyperlipidemic agent, which is marketed as Mevalotin in Japan, and other Asian and European countries. It also offers Calblock and Artist, which are antihypertensive products; Loxonin, an anti-inflammatory analgesic; Omnipaque, a contrast agent; Kremezin for the treatment of chronic renal failure; Urief for treating dysuria; and Sunrythm, an antiarrhythmic agent. In addition, the company?s products comprise Venofer for the treatment of iron deficiency anemia; and WelChol, an antihyperlipidemic agent for the treatment of diabetes. Further, Daiichi Sankyo has various product candidates under clinical development pipeline focusing on the treatment of cardiovascular diseases, malignant neoplasm, glucose metabolic disorders, infectious diseases, immunological allergic diseases, and bone/joint diseases. It also engages in the manufacture and sale of OTC drugs, cosmetics, medical equipments, food and beverage products, and agrochemicals and chemicals; manufacture of active pharmaceutical ingredients and intermediates, veterinary medicines, and raw materials for pharmaceuticals; and provision of agency services. The company has an agreement with Amgen Inc. for the development and marketing of Denosumab in Japan; a sublicense agreement with Fresenius Medical Care for the manufacture and distribution of Venofer; and a collaboration agreement with Ranbaxy for marketing Olmesartan in India. It operates primarily in Japan, North America, Europe, and India. The company was founded in 1899 and is headquartered in Tokyo, Japan.